Homozygous loss-of-function mutations in the transcription factor LHX3 have been associated with hypopituitarism with structural anterior pituitary defects and cervical abnormalities with or without restricted neck rotation. We report two novel recessive mutations in LHX3 in four patients from two unrelated pedigrees. Clinical evaluation revealed that all four patients exhibit varying degrees of bilateral sensorineural hearing loss, which has not been previously reported in association with LHX3 mutations, in addition to hypopituitarism including adrenocorticotropic hormone deficiency and an unusual skin and skeletal phenotype in one family. Furthermore, re-evaluation of three patients previously described with LHX3 mutations showed they also exhibit varying degrees of bilateral sensorineural hearing loss. We have investigated a possible role for LHX3 in inner ear development in humans using in situ hybridization of human embryonic and fetal tissue. LHX3 is expressed in defined regions of the sensory epithelium of the developing inner ear in a pattern overlapping that of SOX2, which precedes the onset of LHX3 expression and is known to be required for inner ear and pituitary development in both mice and humans. Moreover, we show that SOX2 is capable of binding to and activating transcription of the LHX3 proximal promoter in vitro. This study therefore extends the phenotypic spectrum associated with LHX3 mutations to encompass variable sensorineural hearing loss and suggests a possible interaction between LHX3 and SOX2 likely to be important for development of both the inner ear and the anterior pituitary in human embryonic development.
INTRODUCTION
The pituitary gland is a central regulator of growth, reproduction and homeostasis, mediated via hormone-signaling pathways which act to regulate the finely balanced homeostatic control in vertebrates. The gland is situated in the midline at the base of the brain and consists of the anterior and intermediate lobes, which derive embryologically from an invagination of the oral ectoderm (termed Rathke's pouch), and the posterior lobe, which develops from the neural ectoderm of the ventral diencephalon. Hormones secreted from the anterior pituitary are produced from specific cell types within the gland: somatotropes (secreting growth hormone, GH), thyrotropes (thyroidstimulating hormone, TSH), corticotropes (adrenocorticotropic hormone, ACTH), lactotropes (prolactin, PRL) and gonadotropes (follicle-stimulating hormone, FSH, and luteinizing hormone, LH). The intermediate lobe contains melanotropesproducing pro-opiomelanocortin (POMC), which is the precursor to melanocyte-stimulating hormone in addition to endorphins. POMC is also the precursor to ACTH and is also expressed in corticotropes in the anterior pituitary. † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors. Congenital hypopituitarism can range from mild, involving deficiency of a single hormone, through more severe phenotypes affecting multiple pituitary hormone axes, to panhypopituitarism. Isolated growth hormone deficiency is the most common manifestation affecting between 1 in 4000 and 10 000 live births (1) (2) (3) (4) (5) . Combined pituitary hormone deficiency (CPHD), in which GH deficiency is accompanied by insufficiency of at least one other pituitary hormone, is less common, but is associated with considerable morbidity and, if not treated promptly or adequately, occasional mortality. Recent advances in our understanding of the development of the pituitary gland have led to the identification of the etiological basis of some cases of congenital hypopituitarism. Naturally occurring and transgenic murine models have revealed that normal anterior pituitary development is dependent upon a complex genetic cascade of signaling molecules and transcription factors (reviewed in 6). Mutations in several of these genes are associated with CPHD, often with additional extra-pituitary phenotypes, including POU1F1 (MIM 173110), PROP1 (MIM 601538), HESX1 (MIM 601802), SOX3 (MIM 313430), SOX2 (MIM 184429), LHX3 (MIM 600577) and LHX4 (MIM 602146) (reviewed in 7). In several cases, different mutations within the same gene have been reported to lead to variable phenotypes.
We now describe four patients from two unrelated consanguineous pedigrees with novel mutations in the LIM homeodomain transcription factor LHX3. All four patients presented with early-onset hypopituitarism and neonatal hypoglycemia. Subsequent clinical evaluation revealed that all four patients exhibit varying degrees of sensorineural hearing loss which has not previously been reported in association with LHX3 mutations. We show that during human embryonic development, LHX3 is expressed in a restricted region in the inner ear within a domain of cells expressing the transcription factor SOX2, which parallels the expression pattern previously observed in the mouse (8, 9) . Loss or downregulation of Sox2 expression also results in pituitary abnormalities, deafness and morphological defects of the inner ear in mice (10, 11) , and sensorineural hearing loss has been reported as part of the phenotypic spectrum associated with SOX2 mutations in human patients (10, 12) . We demonstrate that the proximal promoter region of LHX3 contains a binding site for SOX2, which is capable of activating a luciferase reporter construct containing this region in vitro. Taken together, these data suggest that SOX2 is likely to play a role in the regulation of LHX3 expression, and that both genes are potentially acting in similar molecular pathways during normal development of the anterior pituitary and the inner ear in humans.
RESULTS
Three affected siblings from family A (see pedigree, Fig. 1 ) exhibited an unusual phenotype consisting of panhypopituitarism, severe anterior pituitary hypoplasia, skeletal abnormalities, hyperextensible joints, loose skin and sensorineural hearing loss. In order to identify the underlying genetic defect, we adopted a homozygosity mapping strategy; affected individuals IV:2, IV:5 and IV:6, together with their unaffected sibling (individual IV:3), were genotyped for 11 555 SNP markers with an average inter-marker distance of 210 kb. The mean SNP genotype call rate obtained was 94.06% (84.59 -98.36%) providing an average 10 868 genotypes per individual. Three significant regions of homozygosity shared between all three affected individuals were identified: a 2.3 Mb region on chromosome 2p24 flanked by markers rs2380657 and rs728679; a 3.9 Mb region on chromosome 12q24 (rs2013160 to rs1918210) and a 7 Mb region on chromosome 9q34-qter defined by markers rs951302 and rs1105176, the most distal marker on the array. Unaffected individual IV:3 was heterozygous for all three of these regions.
No gene in either of the loci on chromosomes 2p24 and 12q24 was a suggestive candidate for the phenotypes manifested by the patients. The region on chromosome 9q34-qter contains the transcription factor LHX3 which presented as an excellent candidate, as mutations in the gene have previously been associated with CPHD (13 -15) . Sequencing of LHX3 in the affected individuals showed that all three were homozygous for an intragenic deletion of 3088 bp (c.80-532_775þ454del3088 relative to LHX3A; NM_178138), resulting in complete loss of exons 2 -5 (Fig. 1A) . The unaffected parents and siblings of the affected patients were all heterozygous with respect to the deletion (Fig. 1B) .
Subsequently, we ascertained a second unrelated family (family B) with a single affected individual manifesting a very similar phenotype consisting of CPHD, pituitary and skeletal abnormalities and sensorineural deafness. Screening of the LHX3 coding sequence in this patient revealed a homozygous transversion c.267A.T (LHX3A; NM_178138), resulting in a nonsense mutation in exon 2 (p.K50X; Fig. 1C) ; both unaffected parents were heterozygous carriers of the mutation.
Clinical re-evaluation of patients previously reported with LHX3 mutations On the basis of the finding of sensorineural hearing loss in these patients, which has not previously been associated with LHX3 mutations, we re-investigated three patients previously reported with homozygous loss-of-function mutations in LHX3 who were available for further evaluation (13) . Two siblings (AII-1 and AII-4 from reference 13) homozygous for a p.Y116C mutation were found to exhibit moderate (60 dB) and mild (30 dB) sensorineural hearing loss. A single patient from the second family [patient BII-1 described by Netchine et al. (13) ], harboring an intragenic deletion of 23 bp, who suffers extreme mental retardation, was diagnosed to be completely deaf on the basis of the absence of any acoustic evoked potential (AEP).
Expression of LHX3 in the inner ear during human embryonic and fetal development
In order to investigate a potential role for LHX3 during development of the inner ear, we investigated its expression pattern in available sections of normal human embryos. LHX3 transcripts were detected in Rathke's pouch and the developing anterior pituitary from CS13 to CS20, in addition to discrete regions of the developing neural tube corresponding to motorneuron and interneuron subpopulations consistent with previous observations (16) (data not shown).
Expression of LHX3 was observed within distinct domains of the developing inner ear from CS20 onwards; no expression was detected by in situ hybridization prior to this stage. LHX3 transcripts were observed in defined regions of the vestibular sensory epithelium at CS20, and expression was maintained from this stage and during all fetal stages investigated (up to 9 weeks of development; Fig. 2A ). This restricted expression pattern was reminiscent to that we have previously observed for SOX2; however, SOX2 is expressed prior to the onset of LHX3 expression (data not shown). Moreover, while these studies were being performed, Hume et al. (8) reported that Sox2 and Lhx3 exhibit overlapping expression patterns during critical periods of inner ear development in the mouse. We subsequently analyzed expression of both genes in serial sections from the developing human inner ear. LHX3 transcripts were observed in the vestibular epithelium in a defined subset of cells within the SOX2 expression domain (Fig. 2B ). In addition, these cells also express ATOH1 (MIM 601461), an essential marker required for hair cell differentiation (17) , suggesting that these correspond to the differentiating vestibular hair cells (Fig. 2B ) in a pattern identical to that observed during murine vestibular morphogenesis (8) .
SOX2 transcripts and protein were also detected within a restricted domain in the dorsal region of the auditory epithelium of the developing cochlear duct at CS17 (Fig. 2C) . Expression is maintained within distinct regions of the developing cochlea, and by fetal stage F2, defined domains of expression are detected in the cochlea corresponding by position to regions from which the sensory hair cells will differentiate ( Fig. 2C ; data not shown). No expression of LHX3 was detected by in situ hybridization in the cochlea sensory epithelium between CS17 and fetal stage F2 (9 weeks of development), the latest stage for which tissue was available to study.
In the mouse, Lhx3 is expressed exclusively within both the vestibular and cochlea hair cells in a pattern overlapping that of Sox2. Moreover, in the cochlea sensory epithelium, Sox2 expression precedes that of Lhx3, the latter is not detectable until late embryonic stages (after E15.5) and maintained postnatally as the cochlea hair cells differentiate (8, 9) . Within the vestibular sensory epithelium, both Sox2 and Lhx3 are expressed at an earlier stage in the mouse, which parallels our observations in human development, suggesting that the pattern of Lhx3 expression in the inner ear may also be conserved in humans. Therefore, onset of LHX3 expression in the cochlea is likely to occur later during fetal development as the hair cells begin to differentiate, at 11 to 12 weeks of human development (18) , beyond the stage for which human fetal material was available for study.
SOX2 is capable of activating LHX3 expression in vitro
Given the observation that expression of SOX2 precedes the onset of LHX3 in an overlapping domain of expression within both the inner ear and pituitary during human development ( Fig. 2) (19) , we hypothesized that SOX2 could be involved in the transcriptional regulation of LHX3. Analysis of the proximal promoter of LHX3 using Matinspector software (Genomatix) identified a putative SOX-binding site at -2213 to -2224 bp relative to the start of transcription of LHX3A (NM_178138), to which SOX2 is capable of binding in vitro (Fig. 3A) . The specific binding of SOX2 to this sequence is further supported by repeating the experiments using a mutated probe to which SOX2 was unable to bind (Fig. 3A) . Luciferase reporter assays co-transfecting CHO cells, which do not express Sox2, with increasing amounts of a SOX2 expression construct together with a reporter construct comprising a 557 bp fragment of the LHX3 proximal promoter containing the SOX2-binding site resulted in a dose dependent activation of the reporter up to a maximum of 9-fold compared with reporter alone (Fig. 3B) . Transfection of the reporter into the human EC cell line NT2/D1, which shows endogenous SOX2 expression (20) (data not shown), led to an 3-fold increase in reporter gene activation compared with the promoter-less reporter. A reporter construct in which the SOX2-binding site had been mutated showed significantly decreased reporter gene activation compared with the wild-type construct (P , 0.006; Fig. 3C ). Electrophoretic mobility shift assays using nuclear extracts prepared from NT2/D1 cells showed a protein:DNA complex interacting with a probe containing the putative SOX2-binding site; addition of anti-SOX2 antibody resulted in a slower migration of the protein complex indicating the specific binding of SOX2 to the probe. No protein was observed binding to the mutated probe using NT2/D1 nuclear extracts or to either probe using CHO cell extracts ( Fig. 3D ; data not shown).
DISCUSSION
In the mouse, Lhx3 expression is crucial during normal pituitary organogenesis for the commitment of the hormoneproducing cell types within the anterior pituitary gland and activation of pituitary-specific genes during development (21, 22) . Lhx3 null mice die before or shortly after birth, exhibiting loss of the anterior and intermediate lobes of the pituitary which form initially but then fail to proliferate and differentiate (23) .
We describe two novel homozygous mutations in LHX3: an intragenic deletion of 3088 bp encompassing exons 2 -5 and a novel nonsense mutation, p.K50X; both are predicted to result in loss of function as a result of a truncated protein or degradation of the mutant transcript by nonsense-mediated decay (24). The phenotypes of the affected patients include some unusual clinical features which have not previously been described in association with LHX3 mutations (Table 1 ) (13 -15) . The patients in family A all show signs of severe early-onset hypopituitarism with neonatal hypoglycemia. A presumptive diagnosis of ACTH deficiency was made on the basis of the clinical phenotype as well as low random cortisol concentrations, whereas previously described patients with LHX3 mutations had preserved ACTH secretion (13, 14) . Unfortunately, apart from patient IV:5 who did not respond to glucagon stimulation by increasing cortisol secretion, formal provocation could not be performed to assess cortisol concentrations. ACTH stimulation performed in the proband in family B unequivocally confirmed a diagnosis of ACTH deficiency, thereby establishing this as a novel feature of LHX3 deficiency. Initial corticotrope specification is usually spared in Lhx3 2/2 mice; however, early in pituitary development, there is a severe reduction in differentiated corticotrope cells and lower expression of corticotrope transcription factors (25) . In addition, it is important to note that the adrenal glands were hypoplastic, and mutants were either stillborn or died within 24 h of birth; therefore, it would not be totally unexpected to diagnose ACTH deficiency in patients with LHX3 mutations.
We report here, for the first time to our knowledge, the association of sensorineural hearing loss in association with mutation of LHX3 in all four patients we describe. Furthermore, clinical re-evaluation of three previously published patients has revealed that these also exhibit varying degrees of sensorineural hearing loss. This association can be explained by a potential role for LHX3 in inner ear sensory hair cell development. In the mouse, Lhx3 is detectable at the basal end of the cochlea specifically in differentiating sensory hair cells, beginning at embryonic day (E) 15.5, within a domain of Sox2-expressing cells (8) . By E17, Lhx3 begins to be expressed in the basal and middle cochlea in both inner and outer hair cells where expression levels increase until birth (8, 9) . Further implication of a role for LHX3 in sensory hair cell development comes from the observation that Lhx3 mRNA is downregulated specifically in the cochlea hair cells in the inner ears of mice with mutation of Pou4f3, mutations in which cause non-syndromic hearing loss in humans (DFNA15; MIM 602459), suggesting that Lhx3 is required for cochlea hair cell differentiation and is regulated in part either directly or indirectly by Pou4f3 specifically in the cochlea sensory epithelium (9) .
In the vestibule, Lhx3 is expressed at earlier stages of embryonic development than in the cochlea, becoming first detectable at 
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Human 8) . Consistent with this, we observed a restricted domain of LHX3 expression overlapping that of SOX2 in the vestibular epithelium; the latter being expressed prior to the onset of LHX3 expression. Furthermore, co-expression of LHX3 with ATOH1 also parallels the expression pattern observed in the mouse, suggesting that expression of LHX3 in the inner ear is highly conserved between species. This is also consistent with our observation of early expression of SOX2 in both the cochlea and vestibular sensory epithelia. Taken together, these data suggest that LHX3 is also likely to be expressed within the differentiating hair cells during human inner ear development. Despite the lack of any detectable LHX3 in fetal stages we investigated, the onset of LHX3 expression in the cochlea is likely to occur as the hair cells differentiate which begins later during fetal development, beyond the stage for which samples were available. It is unclear at present whether our patients exhibit any vestibular defects on account of the skeletal, vertebral and motor deficits in these individuals and also there is a lack of detailed imaging of the inner ear and formal vestibular function testing. However, AEP in two patients (AII-1 and AII-4 from reference 13) suggested a defect in the cochlea, rather than in the acoustic nerve. Distortion product otoacoustic emissions from the mildly affected sibling revealed a defect limited to the 1-2 kHz range, suggesting a defect of the outer hair cells within the cochlea. It could be argued that untreated hypothyroidism in the affected individuals could be associated with hearing loss, as observed in hyt/hyt mutant mice (26) . However, in family A, thyroxine was commenced by the second week of life in all three individuals, although compliance may have been suboptimal in patient IV-1. In family B, the proband was commenced on thyroxine by the age of 2 weeks, suggesting that the deafness could not be attributed to untreated hypothyroidism. In the previously published families with LHX3 mutations (13), AII-4 with mild sensorineural hearing loss was commenced on thyroxine within the first few days of life, whereas the moderately affected AII-1 and more severely affected BII-I were treated much later. Hence, our data suggest that the sensorineural deafness is associated with homozygous loss of LHX3, although untreated hypothyroidism may well contribute to the severity. It is also important to note that the sensorineural hearing deficit may be mild and therefore easily missed in some patients.
The ability of SOX2 to bind to a site in the promoter of LHX3 and activate a luciferase reporter construct in vitro, together with the fact that SOX2 expression in the human embryonic inner ear commences prior to the onset of LHX3 expression, as also observed in the mouse (8, 11) , suggests that SOX2 is capable of directly regulating LHX3. This hypothesis may also be important during pituitary organogenesis, as SOX2 and LHX3 also show consecutive and overlapping expression domains within the developing anterior pituitary in humans (16, 19) . The putative SOX2-binding site that we have identified also lies within a region of the LHX3 promoter previously shown to be involved in active LHX3 expression (22701 to 21581) in the mouse gonadotrope cell line, LbT2 (27) . Although it is unlikely that this cell line expresses Sox2, this site may represent an enhancer region involved in specific temporal and/or spatial expression of LHX3 during pituitary differentiation. Sensorineural hearing loss and anterior pituitary hypoplasia are part of the spectrum of phenotypes associated with SOX2 mutations (10,12). Moreover, Sox2 heterozygous null mice exhibit anterior pituitary hypoplasia (10) , and regulatory mutations affecting Sox2 can result in absent or disordered sensory hair cell formation in mice (11) . Taken together, these data suggest that a genetic interaction between SOX2 and LHX3 may be important for normal development of the anterior pituitary and auditory hair cell differentiation during embryogenesis in both mice and humans; however, conditional deletion of these genes singly and in combination in mice will be necessary to confirm the importance of this interaction.
The intragenic deletion in LHX3 that we report in family A is difficult to reconcile with other phenotypic features (15) observed such as increased skin laxity and skeletal abnormalities. There is a distinct possibility that the deletion may have disrupted regulatory elements of another gene implicated in connective tissue formation. However, Pfaeffle et al. (15) recently described a case with an entire deletion of LHX3 and no similar skin phenotype was reported. Alternatively, it is possible that a second recessive mutation may be segregating between the affected individuals in family A. This study therefore extends the phenotypic spectrum associated with LHX3 mutations to encompass ACTH deficiency and sensorineural hearing loss; the latter can be explained by the likely role of LHX3 in inner ear sensory hair cell development. Given the variable nature of the phenotype, particularly the mild sensorineural deafness we have observed in some patients, further careful phenotypic characterization in patients with LHX3 mutations will shed further light on the role of this gene in human development.
MATERIALS AND METHODS

Family A
Individual IV:1. This female Middle Eastern patient was the second child of healthy consanguineous parents following an uneventful pregnancy (see pedigree, Fig. 1 ). Birth weight was 3.5 kg (0.22 SDS), with an occipito-frontal circumference (OFC) of 35 cm (20.51 SDS) and a length of 51 cm (0.49 SDS). Large anterior and posterior fontanelles, coarse facies, low set ears, short neck, redundant skin folds, increased skin laxity and dislocatable hips were noted on initial examination. Hypoglycemia was apparent on the second day of life. Thyroid function was abnormal, with a total T4 of 2.28 mg/dl (normal range, NR 5 -11.7 mg/dl) and TSH of 0.9 mU/l (NR 1 -6 mU/ l); basal cortisol was 2 mg/dl at 16 h (NR 3.5-10.9 mg/dl). Further assessment revealed low concentrations of ACTH, PRL (0.6 mg/l), LH and FSH (Table 2) . GH stimulation using L-Dopa revealed severe GH deficiency (peak GH 0.33 mg/l), confirmed using insulin-induced hypoglycemia as a second test (GH peak 0.32 mg/l at the time of hypoglycemia). Treatment with thyroxine and hydrocortisone was commenced at 2 weeks of age, and recombinant hGH treatment added at the age of 4 years. Spontaneous pubertal development failed to occur and at 16 years of age, a gonadotropin-releasing hormone (GnRH) test failed to elicit a gonadotropin response (peak LH 0.1 IU/l; peak FSH 0.1 IU/l), with low estradiol concentrations (85 pmol/l; NR 231-726 pmol/l). MRI of the brain and hypothalamo-pituitary region revealed anterior pituitary hypoplasia with a normally placed posterior pituitary and no other midline abnormalities. At the age of 17 years, the patient was short (height 118 cm; 27.4 SDS) with hyperextensible joints, soft hyperelastic skin and deep palmar and plantar creases with hypoplastic nails; she also had dental caries, short neck, broad thorax, lumbar lordosis and kyphoscoliosis and limited neck rotation. Mild flattening of the vertebral bodies, marked thoracolumbar kyphosis, hypoplastic T12 and anterior wedging of L1 were noted, together with a mild degree of spinal stenosis indicated by narrow interpedicular distances and short pedicles of the lumbar spine. Mild (30 dB) sensorineural hearing loss was diagnosed on an audiogram. Because of learning difficulties she attended a school for handicapped children.
Individual IV:4. The younger sister of patient IV:1 was born with a birth weight of 3.6 kg (0.43 SDS), OFC of 36 cm (1.25 SDS) and length of 52 cm (1.2 SDS). Poor feeding, sluggish activity, hypothermia and hypoglycemia were apparent on the second day of life. Thyroid function was abnormal at birth with a free thyroxine (FT4) of 0.2 ng/dl (NR 0.8-2.9 ng/dl) and TSH ,0.2 mU/l. There was no rise in TSH after thyrotropin-releasing hormone (TRH) stimulation. A diagnosis of CPHD was confirmed with low concentrations of early morning cortisol, and treatment commenced with hydrocortisone and thyroxine. GH provocation with clonidine revealed a complete lack of GH response (,1.5 mg/l) with a low concentration of IGF-I, and treatment with rhGH was commenced. Posterior pituitary function was intact. Delayed closure of cranial fontanelles was manifest at the age of 2 years.
Examination at the age of 13 years revealed short stature (height 128 cm; 24 SDS and weight 38 kg; 20.8 SDS) and relative macrocephaly (head circumference 55 cm; 1.1 SDS) with frontal bossing, maxillary hypoplasia, a pointed chin, short neck, lumbar kyphosis and lordosis and long arms; hypermobile joints, soft hyperelastic skin, deep palmar and plantar creases and dental caries were also noted. Radiographic examination revealed slender osteoporotic bones and mild thoracic kyphoscoliosis. Narrowing of the interpedicular distances was observed in the lumbar spine with low set L-5 vertebrae between the iliac wings. She was completely prepubertal. Mild sensorineural hearing loss bilaterally was detected on audiogram (40 dB in the left ear, 30 dB right). The patient had schooling difficulties and attended a school for mentally handicapped children. Individual IV:5. The younger brother of patients IV:1 and IV:4 was born by Caesarean section at full term. The birth weight was 3.6 kg (0.1 SDS), with an OFC of 36 cm (0 SDS) and a length of 48 cm (21.5 SDS). Excessive skin laxity, micropenis and cryptorchidism were noted at birth. On the first day of life, he presented with mild respiratory distress, hypoglycemia and neonatal jaundice. Cord TSH was 0.02 mU/l with an FT4 of 0.4 ng/dl (NR 0.8-2.9 ng/dl). Supplementation with thyroxine and hydrocortisone was commenced in the second week of life, following documentation of low cortisol concentrations at the time of hypoglycemia. Glucagon stimulation performed after cessation of hydrocortisone treatment for 48 h at 9 months of age revealed poor GH (peak ,1.1 mg/l) and cortisol (peak ,2.5 mg/dl) responses. There was no evidence of impairment of posterior pituitary function. Basal testosterone at the age of 6 months was 0.09 ng/ml, with undetectable gonadotropins (LH ,0.1 IU/l, FSH ,0.1 IU/l) on GnRH testing. There was no testosterone response to human chorionic gonadotropin (HCG) stimulation over 3 days (testosterone 0.09 ng/ml post-stimulation) and a minimal response to 3 weeks of HCG (0.14 ng/ml).
The clinical phenotype was similar to that of patients IV:1 and IV:4, with short stature, facial dysmorphism, short broad neck and thoracolumbar kyphosis with exaggerated lumbar lordosis. Hyperelastic skin, hyperextensible wrist, elbow and knee joints, deep palmar and plantar creases, mild nail hypoplasia and dental caries were similar to his sisters. Radiological examination revealed anterior wedging of L1, pseudoepiphyses of I-IV metacarpals, narrowing of interpeduncular distances of the lumbar vertebrae, low set L5, hypoplasia of T12, anterior wedging of L1 and posterior scalloping of lumbar vertebral bodies. Neurological examination was unremarkable, with the exception of mild (30 dB) sensorineural hearing loss bilaterally. Cognitive function was normal for his age, however language development was delayed.
Family B
The single affected individual in this family, a male, was born at 41 weeks to first-degree consanguineous parents, with a birth weight of 3.77 kg (0.45 SDS). Examination at birth revealed mild dysmorphic features including macrocephaly, a short neck, crowding of facial features, large anterior and posterior fontanelles and short limbs, with no evidence of genital abnormalities, and normally descended testes. An atrial septal defect was diagnosed. Neonatal hypoglycemia was noted at 12.5 h of age. Investigations revealed a basal cortisol of 2.4 mg/dl (65 nmol/l) with a peak of 10 mg/dl (276 nmol/l) in response to synacthen stimulation, and a peak GH of 0.08mg/l in response to arginine provocation. The FT4 concentration was ,0.2 ng/dl (,2.5 pmol/l), with an absent TSH response to TRH stimulation (TSH peak ,0.1 mU/l). Repeat testing confirmed GH deficiency in response to arginine provocation (peak GH 0.2 mg/l, NR . 5.8 mg/l; IGF1 , 25 ng/ml, NR 40-195 ng/ml). PRL was also low (4 mg/l). He was commenced on thyroxine and hydrocortisone within 2 weeks of birth and GH at 4 weeks and responded well to treatment.
MRI revealed anterior pituitary hypoplasia with a eutopic posterior lobe and a normal infundibulum. No other intracranial abnormalities were identified. Subsequently, audiological assessment demonstrated profound bilateral sensorineural deafness (96 dB), requiring the use of hearing aids. He also had evidence of motor delay and was hypotonic. He developed the appearance of a skeletal dysplasia, with a short neck, stiff back and gibbus and prominent frontal bones of the cranial vault. Skeletal survey revealed a localized thoracic kyphosis at L1, with slight beaking of the inferior aspect of the L1 vertebral body. The interpedicular distance in the lumbar spine was slightly reduced, but was within the NR.
Hormonal testing. For the assessment of GH secretion, glucagon was administered intramuscularly at a dose of 100 mg/kg, and sampling performed at 30 min intervals over 3 h. Cortisol concentration was measured at 0, 150 and 180 min after glucagon administration. Clonidine was administered at a dose of 0.15 mg/m 2 , and sampling performed every 30 min over a 2 h period. TRH was administered intravenously at a dose of 7 mg/kg, and TSH measured at 0, 20 and 60 min. GnRH was administered at a dose of 2.5 mg/kg intravenously and LH and FSH measured at 0, 20 and 60 min. HCG (500 units daily intramuscularly) was administered over a 3 day period, and testosterone measured on day 1 and day 4, 24 h after the administration of the last dose. Fasting paired plasma and urine osmolalities were measured early in the morning. GH was measured using a double radioimmunoassay (detection limit 0.9 ng/ml), and LH and FSH were measured using an automated two-step immunometric assay (Axsym, Abbot Laboratories, Maidenhead, UK). Testosterone was assayed by coated-tube radioimmunoassay (Diagnostic Products Corporation, Los Angeles, CA, USA). Thyroxine and TSH were measured using chemiluminescent microparticle immunoassays. Serum cortisol was measured using a fluorescence polarization immunoassay. For family B, arginine monochloride (10% solution) was infused over 30 min at 0.5 g/kg up to a maximum of 30 g, and sampling performed at 15 min intervals for 1 h, then at 90 and 120 min. A standard synacthen test was performed, involving intravenous administration of 36 mg/kg synacthen and sampling for cortisol measurements at 0, 30 and 60 min. TRH testing was performed as described earlier. GH and IGF-1 were measured using solid-phase, two-site and enzyme-labeled chemiluminescent immunometric assays, respectively. FT4 and TSH were measured using solid-phase chemiluminescent competitive analog immunoassay and immunometric assay, respectively. Cortisol was measured using solid-phase competitive chemiluminescent enzyme immunoassay, with all assays analyzed using Immulite 2000 (Siemens Medical Solutions Diagnostic).
Genotyping and homozygosity mapping. SNP genotyping was performed using the GeneChip Mapping 10K Array and Assay kit (Affymetrix Inc., Santa Clara, CA, USA) according to the manufacturer's protocol. Arrays were scanned using an Affymetrix Fluidics Station F450 and images obtained using an Affymetrix GeneArray scanner 3000. SNP genotype, marker order and chromosomal location were derived using GCOS/GDAS (Affymetrix), and genotype data were analyzed using ExcludeAR3 (28) .
Generation of riboprobes.
A 664 bp fragment from human LHX3 cDNA was amplified by PCR using the following primers: sense 5 0 -GAGGTAGACCACGCTCAGTT-3 0 and antisense 5 0 -CCACAGGATACTCGAGAACA-3 0 and cloned into the pCR4-TOPO vector (Invitrogen). Antisense and sense probes were generated by in vitro transcription, incorporating Digoxigenin-dUTP using the DIG RNA labeling mix (Roche). The probe for Atoh1 has been described previously (29) and was a kind gift of Dr Jane E. Johnson.
Electrophoretic mobility shift assay. SOX2 protein was generated using the TNT Quick Coupled Transcription/Translation System (Promega). Nuclear extracts were prepared by harvesting cells in cytoplasmic lysis buffer (10 mM HEPES, 1 mM EDTA, 100 mM EGTA, 10 mM KCl, 1 mM DTT, 1 mM sodium pyrophosphate, 1 mM sodium vanadate) containing Protease Inhibitor Cocktail (Sigma), followed by cell lysis using 0.6% NP40 (Sigma). Nuclei were pelleted by centrifugation, resuspended in nuclear lysis buffer (20 mM HEPES, 0.2 mM EDTA, 0.1 mM EGTA, 25% glycerol, 20 mM NaCl, 1 mM DTT, 1 mM sodium pyrophosphate, 1 mM sodium vanadate) and lysed by repeated freeze thawing followed by centrifugation to remove nuclear debris. EMSAs were performed as described previously (30, 31) , using a radio- Plasmid constructs. PCR products comprising a 577 bp fragment of the proximal promoter of LHX3 from 22463 to 21887 relative to the start of transcription of LHX3A (NM_178138) were generated from human genomic DNA using the following primers: sense 5 0 -TTTGTGGCTATTG GTGTGTC-3 0 and antisense 5 0 -GGGTTCAAAGGCAAATAC AC-3 0 . Purified PCR products were cloned into pGL4.10 (Promega). Mutation of the putative SOX2-binding site within this region was performed using the Quikchange Site Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. The expression construct containing the human SOX2-coding sequence has been described previously (10) .
Cell culture and transient transfection. CHO and NT2/D1 cells were maintained in DMEM supplemented with 10% fetal bovine serum and 2 mM L-glutamine at 378C in humidified air containing 5 and 10% CO 2 , respectively. Transient transfection assays were performed using Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions in a 96-well tissue culture plate. Cells were either co-transfected with 20 ng of luciferase reporter construct, together with increasing amounts of SOX2 expression construct (1-75 ng), or 100 ng of luciferase reporter construct alone. pRLSV40 (Promega) was co-transfected in all experiments to control for transfection efficiency, and the total amount of transfected DNA was normalized to 120 ng/well for CHO cells and 100 ng/well for NT2/D1 cells by the addition of empty expression vector. Cells were harvested following transfection and assayed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega), using a BMG Fluostar Optima microplate reader. Transfection experiments were each repeated three times independently and performed in triplicate; data are presented as mean + standard deviation.
In situ hybridization. Analysis of human embryonic/fetal material was performed by the MRC-Wellcome Trust Human Developmental Biology Resource in situ hybridization service with full ethical approval from the joint Great Ormond Street Hospital NHS Trust/Institute of Child Health ethics committee.
Human embryos/fetuses at selected stages were dissected and fixed in 4% PFA, then dehydrated and embedded in paraffin wax. Sections of 7 mm were cut using a standard microtome and mounted on Superfrost Plus slides (BDH). In situ hybridization was performed essentially as described by Wilkinson (32) . For antibody detection, slides were incubated with anti-digoxigenin antibody conjugated with alkaline phosphatase (diluted 1:1000, containing 2% FCS) overnight at 48C. Expression patterns were visualized using the NBT/BCIP system (Roche). Sections were mounted in VectaMount (Vector Labs) and analyzed using the Axioplan2 imaging system (Zeiss).
Immunohistochemistry. Human embryo and fetal sections were de-waxed and rehydrated. Antigen retrieval was performed by boiling for 10 min in 0.01 M citric acid buffer, pH 6.0. After cooling to room temperature, slides were transferred to TBST (0.5 M Tris Base, 9% NaCl, pH 7.6, 0.025% Triton) and blocked with 10% heat-inactivated rabbit serum (HIRS) (Sigma) in TBST. All antibody incubations were carried out at room temperature in a humidified chamber. Slides were incubated with goat anti-SOX2 antibody (1:500 dilution, Immune Systems Ltd.) in TBST with 1% HIRS. Slides were washed and incubated with a polyclonal rabbit anti-goat IgG biotinylated antibody (1:100 dilution, DAKO). Biotin was detected using streptavidin-Alexa Fluor 555 conjugate in PBS (1:300 dilution, Molecular Probes). Slides were mounted in Vectashield with DAPI (Vector Laboratories) and images captured on a Leica DC500 microscope using Fire Cam Software. 
